News & Updates
Filter by Specialty:
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?
15 Jun 2022
Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?
15 Jun 2022
Familiarity with EuroLupus dosing for cSLE remains low despite uptick in use
15 Jun 2022
Paediatric specialists now use low-dose EuroLupus cyclophosphamide (CYC) more than they did a decade ago in the treatment of childhood-onset systemic lupus erythematosus (cSLE), reports a study in North America. However, familiarity with EuroLupus dosing is still low.
